JP2014509593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509593A5 JP2014509593A5 JP2013558187A JP2013558187A JP2014509593A5 JP 2014509593 A5 JP2014509593 A5 JP 2014509593A5 JP 2013558187 A JP2013558187 A JP 2013558187A JP 2013558187 A JP2013558187 A JP 2013558187A JP 2014509593 A5 JP2014509593 A5 JP 2014509593A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- erbb3
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452976P | 2011-03-15 | 2011-03-15 | |
| US201161452974P | 2011-03-15 | 2011-03-15 | |
| US61/452,974 | 2011-03-15 | ||
| US61/452,976 | 2011-03-15 | ||
| PCT/US2012/029292 WO2012125864A2 (en) | 2011-03-15 | 2012-03-15 | Overcoming resistance to erbb pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509593A JP2014509593A (ja) | 2014-04-21 |
| JP2014509593A5 true JP2014509593A5 (OSRAM) | 2014-06-19 |
Family
ID=45953230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558187A Withdrawn JP2014509593A (ja) | 2011-03-15 | 2012-03-15 | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150231238A1 (OSRAM) |
| EP (2) | EP2815765A1 (OSRAM) |
| JP (1) | JP2014509593A (OSRAM) |
| KR (1) | KR20140023921A (OSRAM) |
| CN (1) | CN103429262A (OSRAM) |
| AU (1) | AU2012229062A1 (OSRAM) |
| BR (1) | BR112013022887A2 (OSRAM) |
| CA (1) | CA2828043A1 (OSRAM) |
| EA (1) | EA201301025A1 (OSRAM) |
| IL (1) | IL228393A0 (OSRAM) |
| MX (1) | MX2013010444A (OSRAM) |
| SG (1) | SG192775A1 (OSRAM) |
| WO (1) | WO2012125864A2 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| JP2013522237A (ja) | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| US9828635B2 (en) | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| US9956276B2 (en) * | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2015048008A2 (en) * | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| TW201601753A (zh) * | 2013-09-30 | 2016-01-16 | 第一三共股份有限公司 | 蛋白質生物標記及其用途 |
| WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| SI3110849T1 (sl) * | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| MX2016014862A (es) | 2014-05-14 | 2017-02-27 | Hoffmann La Roche | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| HK1248539A1 (zh) * | 2015-04-17 | 2018-10-19 | 梅里麦克制药股份有限公司 | 借助塞里班土单抗的组合治疗 |
| WO2016179103A1 (en) | 2015-05-01 | 2016-11-10 | National Taiwan University | Pink1 c-terminal domain polypeptide and methods using the same in cancer treatment |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017035482A1 (en) * | 2015-08-27 | 2017-03-02 | Merrimack Pharmaceuticals, Inc | Combination therapies for treatment of heregulin positive cancers |
| BR112018008068A2 (en) | 2015-10-23 | 2018-11-13 | Merus N.V. | binding molecules that inhibit cancer growth |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| CN108697779B (zh) | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| CA3058343A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene |
| US12195551B2 (en) | 2017-05-17 | 2025-01-14 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
| HUE071182T2 (hu) | 2017-08-09 | 2025-08-28 | Merus Nv | EGFR és CMET kötõ antitestek |
| WO2019088348A1 (ko) * | 2017-11-06 | 2019-05-09 | 한국과학기술원 | Egfr 저해제 저항성 암 치료제 |
| AU2020371040B2 (en) * | 2019-10-24 | 2025-10-09 | Merus N.V. | Means and methods for treating subjects with HER2 and HER3 positive cancer |
| AR127893A1 (es) * | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| CN100424175C (zh) | 2002-03-26 | 2008-10-08 | 上海泽生科技开发有限公司 | ErbB-3 用于肿瘤治疗的方法和组合物 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| PL2132229T3 (pl) | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| JP2010526797A (ja) | 2007-05-11 | 2010-08-05 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物 |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| CN102356092B (zh) * | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| ES2692379T3 (es) * | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
| US20140056898A1 (en) * | 2011-02-24 | 2014-02-27 | Bo Zhang | Combination therapies comprising anti-erbb3 agents |
-
2012
- 2012-03-15 CN CN201280011820XA patent/CN103429262A/zh active Pending
- 2012-03-15 MX MX2013010444A patent/MX2013010444A/es unknown
- 2012-03-15 CA CA2828043A patent/CA2828043A1/en not_active Abandoned
- 2012-03-15 US US14/004,848 patent/US20150231238A1/en not_active Abandoned
- 2012-03-15 KR KR1020137026522A patent/KR20140023921A/ko not_active Withdrawn
- 2012-03-15 EP EP14166702.2A patent/EP2815765A1/en not_active Withdrawn
- 2012-03-15 EA EA201301025A patent/EA201301025A1/ru unknown
- 2012-03-15 BR BR112013022887A patent/BR112013022887A2/pt not_active IP Right Cessation
- 2012-03-15 AU AU2012229062A patent/AU2012229062A1/en not_active Abandoned
- 2012-03-15 SG SG2013061791A patent/SG192775A1/en unknown
- 2012-03-15 JP JP2013558187A patent/JP2014509593A/ja not_active Withdrawn
- 2012-03-15 EP EP12714108.3A patent/EP2686015A2/en not_active Withdrawn
- 2012-03-15 WO PCT/US2012/029292 patent/WO2012125864A2/en not_active Ceased
-
2013
- 2013-09-12 IL IL228393A patent/IL228393A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509593A5 (OSRAM) | ||
| JP2013522237A5 (OSRAM) | ||
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| JP6967853B2 (ja) | ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体 | |
| JP2018052959A5 (OSRAM) | ||
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| JP2024037894A5 (OSRAM) | ||
| JP2013537546A5 (OSRAM) | ||
| JP2015500828A5 (OSRAM) | ||
| JP2015517300A5 (OSRAM) | ||
| JP2017514795A5 (OSRAM) | ||
| JP2016166203A5 (OSRAM) | ||
| JP2017529838A5 (OSRAM) | ||
| HRP20170462T1 (hr) | Protutijela za epidermalni receptor 3 faktora rasta (her3) | |
| JP2010523536A5 (OSRAM) | ||
| EP3603672A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| CA2872226A1 (en) | Humanized pan-her antibody compositions | |
| AU2013201584A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody | |
| US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| RU2012151889A (ru) | Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr | |
| WO2012154587A2 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| US20240398943A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof | |
| JP2017515843A5 (OSRAM) | ||
| EP3169708B1 (en) | Her3 inhibition in low-grade serous ovarian cancers |